论文部分内容阅读
我们自１９８０～１９８８年对７９例复治矽肺结核进行化疗。其中绝大多数为慢性纤维化空洞性病例，均经细菌学证实，并由尘肺诊断组认定为矽肺合并结核。本组病例分别以ＫＭ、ＩＮＨ、ＲＦＰ、ＰＺＡ，或ＳＭ、ＩＮＨ、ＲＦＰ、ＥＢ联合，分两阶段治疗１８个月，获痰菌阴转７９．２％，其中ＫＨＲＺ与ＳＨＲＥ组分别为９３．９％与６８．２％（Ｐ＜０．０５）。自疗程结束追踪２～８年，其细菌复阳率分别为６．４５％和１０．０％（Ｐ＞０．１）。并对影响其过去治疗失败的原因及对策进行了讨论。
We conducted 79 chemotherapy-refractory silicosis cases from 1980 to 1988. The vast majority of them were chronic fibrolatonous cases, both confirmed by bacteriology and diagnosed as pneumoconiosis complicated by tuberculosis. Patients in this group were treated with KM, INH, RFP, PZA or SM, INH, RFP and EB respectively for 18 months in two stages. The sputum negative conversion rate was 79.2%. The KHRZ and SHRE groups were 93 and 93 respectively. 9% and 68.2% (P <0.05). After 2 to 8 years of follow-up, the rates of bacterial complex positive were 6.45% and 10.0%, respectively (P> 0.1). And discussed the reasons and countermeasures that affect the failure of past treatment.